SCHEMBL14904742

SCHEMBL14904742

CCOC(=O)[C@@H]1CCCN1C(=O)c1cccc(N)c1F

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.49
▸ CXCR1 P25024 1/20 0.49
▸ CXCR2 P25025 1/20 0.49
▸ MAPT P10636 1/20 0.45
▸ KMT2A Q03164 4/20 0.44
▸ TSHR P16473 3/20 0.44
▸ NR1D1 P20393 1/20 0.44
▸ KCNK3 O14649 1/20 0.43
▸ KDM4E B2RXH2 3/20 0.42
▸ TDP1 Q9NUW8 2/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ FKBP1A P62942 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18314666 0.89 ALDH1A1 (0.51) ALDH1A1CXCR1CXCR2MAPTKMT2A
SCHEMBL18556227 0.88 ALDH1A1 (0.50) ALDH1A1CXCR1CXCR2MAPTKMT2A
SCHEMBL14904767 0.87 GAA (0.49) CXCR1CXCR2KCNK3
SCHEMBL14904773 0.84 CXCR1 (0.49) CXCR1CXCR2KCNK3NPSR1
SCHEMBL14904738 0.84 MAPT (0.56) ALDH1A1CXCR1CXCR2MAPTKMT2A
SCHEMBL18556235 0.84 MAPT (0.56) ALDH1A1CXCR1CXCR2MAPTKMT2A
SCHEMBL14895028 0.82 CA2 (0.48) ALDH1A1CXCR1CXCR2KMT2AL3MBTL1
SCHEMBL20366865 0.82 ALDH1A1 (0.56) ALDH1A1KMT2ATSHRNR1D1KCNK3
SCHEMBL14895027 0.82 CA2 (0.48) ALDH1A1CXCR1CXCR2KMT2AL3MBTL1
SCHEMBL13469117 0.80 ALDH1A1 (0.54) ALDH1A1KMT2ATSHRNR1D1KCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9388149-B2 Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-07-12 — — US disclosed
US-9388149-B2 Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-07-12 — — US disclosed
EP-2771329-B1 NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES GALDERMA RES & DEV (FR) 2016-03-16 — — EP disclosed
US-20140296254-A1 NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES GALDERMA RESEARCH & DEVELOPMENT (FR) 2014-10-02 — — US disclosed
US-20140296254-A1 NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES GALDERMA RESEARCH & DEVELOPMENT (FR) 2014-10-02 — — US disclosed
WO-2013061004-A1 NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-05-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296254-A1 NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES CCL2, CCL11, CCR1 ALDH1A1 856/4885CXCR1 11/4885CXCR2 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback